3T Biosciences, an immunotherapy company focused on advancing treatments for solid tumors and other immune-mediated diseases, has announced the appointment of Behzad Kharabi, M.D., as chief medical officer, and Karen E. Knudsen, MBA, Ph.D., CEO of the Parker Institute for Cancer Immunotherapy, to its board of directors. These additions bring significant experience in clinical development, translational oncology, and strategic leadership as the company continues to develop its pipeline of bispecific T-cell engager therapeutics for solid tumors.
Stefan Scherer, M.D., Ph.D., CEO of 3T Biosciences, stated that both appointments are timely as the company reaches a pivotal stage in its growth. He highlighted Dr. Kharabi’s leadership in global development programs for some of the most impactful cell therapies, including TECARTUS, a CAR-T therapy for certain blood cancers. Scherer also emphasized that Dr. Knudsen’s experience leading PICI and her broader contributions to the oncology ecosystem will provide valuable guidance as the company expands its pipeline and advances novel T-cell engager candidates.
Dr. Kharabi remarked that T-cell engager therapies are among the most promising approaches in immuno-oncology, particularly for solid tumors where current treatments often fall short. He noted that 3T’s platform enables the discovery and validation of novel, highly specific T-cell receptor targets, offering the potential for therapies with improved potency and safety. He expressed enthusiasm about contributing to the development of these innovative treatments for patients.
Health Technology Insights: EDX Medical to Launch Advanced Bowel Cancer Test in UK
Dr. Knudsen stated that 3T is addressing one of the greatest challenges in immuno-oncology by developing selective and effective TCR therapies for solid tumors. She described the science as compelling and the potential for patient impact as significant. She expressed her commitment to supporting the company as it advances these programs.
Dr. Kharabi brings over 20 years of experience in academic medicine, clinical research, and global drug development, with leadership roles at Janssen Pharmaceuticals, Kite Pharmaceuticals/Gilead Sciences, and T-Knife Therapeutics. He led the clinical development of TECARTUS and has held research positions at Memorial Sloan Kettering Cancer Center and the University of California, San Francisco. He earned his medical degree from the University of Muenster, Germany, and has received multiple research awards, including the Ernst-Jung Award for junior investigators.
Health Technology Insights: Celltrion Wins CHMP Support for SteQeyma Autoinjector
Dr. Knudsen leads the Parker Institute for Cancer Immunotherapy, where she drives cross-institutional collaboration and advances immune-based therapies with the goal of turning all cancers into curable diseases. She is a globally recognized cancer researcher and healthcare leader who previously served as CEO of the American Cancer Society and held senior executive roles at Thomas Jefferson University and Jefferson Health. She has been involved with national committees including the NCI Board of Scientific Advisors, the Association of American Cancer Institutes, the American Society for Clinical Oncology, and the American Association for Cancer Research. Dr. Knudsen holds a doctorate in biological sciences from the University of California, San Diego, and an MBA from Temple University.
These appointments position 3T Biosciences to leverage deep expertise in oncology, clinical development, and strategic leadership as the company continues to advance its innovative T-cell engager therapies for patients with solid tumors and other immune-mediated diseases.
Health Technology Insights: Cosan Secures Growth Funding to Expand AI Virtual Care
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
